- Report
- January 2024
- 200 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2024
- 200 Pages
Global
From €4006EUR$4,150USD£3,436GBP
- Report
- November 2022
- 154 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Drug Pipelines
- March 2022
- 900 Pages
Global
From €8687EUR$9,000USD£7,452GBP
- Report
- February 2022
- 360 Pages
United States
From €3475EUR$3,600USD£2,981GBP
- Report
- February 2020
- 600 Pages
Global
From €3861EUR$4,000USD£3,312GBP
- Report
- October 2018
- 141 Pages
Global
From €603EUR$625USD£517GBP
€1206EUR$1,250USD£1,035GBP
- Report
- January 2023
- 189 Pages
Global
From €4054EUR$4,200USD£3,477GBP
- Report
- February 2022
- 185 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Drug Pipelines
- December 2019
- 80 Pages
Global
From €3378EUR$3,500USD£2,898GBP
- Report
- August 2022
- 417 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- December 2019
- 55 Pages
Global
From €3378EUR$3,500USD£2,898GBP
Cemiplimab is a monoclonal antibody used in the treatment of certain types of cancer. It is used to treat advanced cutaneous squamous cell carcinoma (CSCC) and metastatic non-small cell lung cancer (NSCLC). Cemiplimab works by targeting a protein called PD-1, which is found on the surface of certain immune cells. By blocking PD-1, cemiplimab helps the immune system to recognize and attack cancer cells. Cemiplimab is administered intravenously and is usually given in combination with other cancer treatments.
Cemiplimab is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2018. It is currently the only approved PD-1 inhibitor for the treatment of CSCC and NSCLC.
Some companies in the cemiplimab market include Regeneron Pharmaceuticals, Sanofi, Merck, and Bristol-Myers Squibb. Show Less Read more
